CDSCO Panel denies Nacto Pharma's request To Waive Phase III CT of Anticancer Erdafitinib tablet Dr. Divya Colin13 Aug 2023 6:00 PM ISTNew Delhi: Rejecting the waiver of Phase III clinical trial proposal for Erdafitinib Tablets 3mg, 4mg, and 5mg, the Subject Expert Committee (SEC)...
Natco Pharma net profit rises 31.2 percent to Rs 420.3 crore in Q1 Ruchika Sharma10 Aug 2023 12:30 PM ISTNew Delhi: Natco Pharma Ltd has reported a 31.2 per cent rise in consolidated net profit at Rs 420.3 crore in the first quarter ended June 30, 2023. ...
Natco Pharma seeks USFDA nod for generic Erdafitinib Tablets Ruchika Sharma27 July 2023 11:41 AM ISTHyderabad: NATCO Pharma Limited has announced the submission of Abbreviated New Drug Application (ANDA) containing a paragraph IV certification...
Natco Pharma Vizag facility gets EIR from USFDA Ruchika Sharma16 Jun 2023 1:30 PM ISTHyderabad: Natco Pharma Limited has announced the successful closure of inspection and received Establishment Inspection Report (EIR) from the...
Natco Pharma gets USFDA nod for Tipiracil Hydrochloride and Trifluridine Tablets Ruchika Sharma16 Jun 2023 11:39 AM ISTLonsurf is indicated primarily for the treatment of colorectal cancer.
Natco Pharma posts Rs 715.3 crore of Profit after tax for year ended March 31st, 2023 Ruchika Sharma30 May 2023 1:30 PM ISTThe profit for the fourth quarter, on a consolidated basis was INR 275.8 Crore, as against a loss of INR 50.5 Crore last year fourth quarter.
Natco Pharma to set up subsidiary in Indonesia with investment of Rs 25 crore Ruchika Sharma21 April 2023 11:15 AM ISTNatco will initially invest USD 1 million for a stake of 51 per cent as capital contribution and balance will be invested as and when the funds are...
Natco Pharma rolls out additional strengths for generic version of Revlimid in US Ruchika Sharma10 March 2023 2:15 PM ISTLenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Multiple Myeloma medicine: Natco Pharma unveils Pomalidomide under brand NAT-POMALIDOMIDE in Canada Ruchika Sharma1 March 2023 12:15 PM ISTMultiple myeloma, commonly referred to as myeloma, is a cancer of plasma cells.
Natco Pharma announces submission of ANDA with USFDA for generic version of Olaparib Tablets Ruchika Sharma13 Feb 2023 12:25 PM ISTOlaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer.
Natco Pharma consolidated net profit declines 22 percent at Rs 62 crore in Q3 Ruchika Sharma10 Feb 2023 3:30 PM ISTNew Delhi: Natco Pharma has announced that its consolidated net profit declined by 22 percent to Rs 62 crore for the third quarter ended December 31,...
Natco Pharma gets 2 observations from USFDA for Vizag facility Ruchika Sharma5 Feb 2023 1:00 PM ISTHyderabad: Natco Pharma Limited has announced the completion of a regulatory inspection from the United States Food and Drug Administration (USFDA)...
